本文選題：特比萘芬　切入點：伊曲康唑　出處：《中國醫(yī)院用藥評價與分析》2016年02期

【摘要】：目的:系統(tǒng)評價特比萘芬和伊曲康唑治療甲真菌病的有效性及安全性,為甲真菌病治療中抗菌藥物的選擇提供參考。方法:使用計算機檢索Cochrane臨床對照試驗數(shù)據(jù)庫、EMbase、Pub Med、中國生物醫(yī)學文獻數(shù)據(jù)庫、萬方數(shù)據(jù)庫及手工檢索相關(guān)文獻等,檢索時間段為建庫至2014年11月。查找用英文或中文發(fā)表的比較特比萘芬和伊曲康唑治療甲真菌病有效性和安全性的隨機對照試驗,提取數(shù)據(jù)并進行方法學質(zhì)量評價后,用Rev Man 5.1軟件進行Meta分析。結(jié)果:總共納入10個隨機對照試驗(1 839例患者)進行Meta分析,其中對10個研究(1 839例患者)進行了有效性(真菌治愈率)的評價,特比萘芬組的真菌治愈率優(yōu)于伊曲康唑組,差異具有統(tǒng)計學意義[RR=1.29,95%CI=(1.13,1.46),P0.000 1];9個研究(1 711例患者)報告了不良反應的發(fā)生情況,2組不良反應發(fā)生率無統(tǒng)計學意義[RR=1.04,95%CI=(0.84,1.29),P=0.72];特比萘芬組的胃痛的發(fā)生率顯著高于伊曲康唑組(P=0.05),而肝功異常的發(fā)生率明顯低于伊曲康唑組(P≤0.05)。所有試驗中均未觀察到嚴重不良反應。結(jié)論:現(xiàn)有的臨床研究證據(jù)顯示,特比萘芬治療甲真菌病的療效優(yōu)于伊曲康唑,且無嚴重不良反應。
[Abstract]:Objective: To evaluate the efficacy and safety of terbinafine and itraconazole in the treatment of onychomycosis, provide a reference for the selection of antibacterial drugs in the treatment of onychomycosis. Methods: using computer controlled trials database, Cochrane EMbase Pub Med, clinical retrieval, Chinese biomedical literature database, Wanfang database and manual search of relevant documents, retrieval time up to November 2014. English Chinese published or search by comparison of terbinafine and itraconazole in the treatment of onychomycosis of the efficacy and safety of randomized controlled trials, method of data extraction and quality evaluation, Meta analysis was carried out using Rev Man 5.1 software. Results: a total of a total of 10 randomized controlled trials (1839 patients) were analyzed by Meta. One of 10 studies (1839 patients) were effective (cure rate of fungi) evaluation, fungi group cure rate naphthalenophane tebi. In the itraconazole group, the difference was statistically significant ([RR=1.29,95%CI= 1.13,1.46, P0.000 1]); 9 studies (1711 patients) had reported adverse reactions, adverse reactions of 2 groups were not statistically significant ([RR=1.04,95%CI= 0.84,1.29), P=0.72]; the incidence rate in group stomach naphthalenophane was significantly higher than that of itraconazole group (P=0.05) however, abnormal liver function was significantly lower than the itraconazole group (P = 0.05). All the tests had no serious adverse events were observed. Conclusion: the clinical study of existing evidence shows that terbinafine is more effective than itraconazole in the treatment of onychomycosis, and no serious adverse reactions.

【作者單位】： 北京大學首鋼醫(yī)院藥劑科;
【分類號】：R756.4

【相似文獻】

相關(guān)期刊論文 前10條

1 孫樂棟;丙烯胺類抗真菌藥特比萘芬研究概況[J];華南國防醫(yī)學雜志;2000年02期

2 王培光,張學軍;特比萘芬的臨床應用研究進展[J];國外醫(yī)學.皮膚性病學分冊;2002年05期

3 李偉,楊如;特比萘芬治療復發(fā)性念珠菌外陰陰道炎46例療效觀察[J];現(xiàn)代婦產(chǎn)科進展;2002年06期

4 于長平,邢國琴,邱勇,吳梅,史本青;特比萘芬超聲透入治療兔模型癬病的研究[J];中國麻風皮膚病雜志;2002年04期

5 張豁達,李燕春,吳彩霞;口服特比萘芬治療外陰陰道念珠菌病療效觀察[J];嶺南皮膚性病科雜志;2003年03期

6 王智群,孫旭光,李然,武宇影;特比萘芬滴眼劑對兔眼刺激性的實驗研究[J];眼科;2004年04期

7 郭健,劉麗,王科梅,李衛(wèi)平,周桂林;1%特比萘芬乳膏治療念珠菌性包皮龜頭炎的療效觀察[J];皮膚病與性病;2004年03期

8 肖志梅;日本修訂特比萘芬警告[J];中國藥師;2004年06期

9 王惠平,亓玉青;口服特比萘芬治療念珠菌性包皮龜頭炎[J];中國麻風皮膚病雜志;2005年08期

10 易恒安;陳雄波;;特比萘芬治療復發(fā)性念珠菌性外陰陰道炎臨床療效觀察[J];實用臨床醫(yī)藥雜志;2006年05期

相關(guān)會議論文 前10條

1 曹志明;;特比萘芬軟膏治療念珠菌性包皮龜頭炎療效觀察[A];2003中國中西醫(yī)結(jié)合皮膚性病學術(shù)會議論文匯編[C];2003年

2 季雅娟;王愛平;劉偉;萬U，

本文編號：1719991